Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.78 |
| ▸ | BACE2 | Q9Y5Z0 | 4/20 | 0.78 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1977272 | 0.90 | BACE1 (0.78) | BACE1BACE2CYP2D6 | |
| SCHEMBL1975402 | 0.87 | BACE1 (1.00) | BACE1BACE2CYP2D6 | |
| SCHEMBL1977233 | 0.87 | BACE1 (0.86) | BACE1BACE2CYP2D6 | |
| SCHEMBL1976782 | 0.87 | BACE1 (0.73) | BACE1BACE2CYP2D6 | |
| SCHEMBL1976786 | 0.87 | BACE1 (0.64) | BACE1BACE2CYP2D6 | |
| SCHEMBL2587828 | 0.87 | BACE1 (0.78) | BACE1BACE2 | |
| SCHEMBL2594391 | 0.87 | BACE1 (0.65) | BACE1BACE2CYP2D6 | |
| SCHEMBL1978654 | 0.87 | BACE1 (0.84) | BACE1BACE2CYP2D6 | |
| SCHEMBL1978644 | 0.87 | BACE1 (0.75) | BACE1BACE2CYP2D6 | |
| SCHEMBL1976469 | 0.87 | BACE1 (0.84) | BACE1BACE2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964594-B1 | Amino oxazine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-06-21 | — | — | US | claimed |
| US-20110144098-A1 | AMINO OXAZINE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2011-06-16 | — | — | US | claimed |
| EP-2509966-B1 | AMINO OXAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-10-22 | — | — | EP | disclosed |
| US-7964594-B1 | Amino oxazine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-7964594-B1 | Amino oxazine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-20110144098-A1 | AMINO OXAZINE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2011-06-16 | — | — | US | disclosed |
| US-20110144098-A1 | AMINO OXAZINE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2011-06-16 | — | — | US | disclosed |
| WO-2011070029-A1 | AMINO OXAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144098-A1 | AMINO OXAZINE DERIVATIVES | BACE2, BACE1, PSEN2 | BACE1 2/4885BACE2 1/4885CYP2D6 187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.